Mebendazole augments sensitivity to sorafenib by targeting MAPK and BCL-2 signalling in n-nitrosodiethylamine-induced murine hepatocellular carcinoma. (2019)

Peer-Reviewed Study · Nancy S Younis; Amal M H Ghanim; Sameh Saber · December 13, 2019

Nancy S Younis et al., 2019-12-13: Mouse hepatocellular carcinoma study in which mebendazole, alone and with sorafenib, lowered BCL-2 and VEGF and reduced tumour growth and markers of proliferation.

Increased hepatic caspases-3 and -9 and decreased BCL-2 levels suggest induced-cell death.

Nancy S Younis et al., 2019-12-13: Mouse hepatocellular carcinoma study in which mebendazole, alone and with sorafenib, lowered BCL-2 and VEGF and reduced tumour growth and markers of proliferation. Study type: N-nitrosodiethylamine-induced mouse hepatocellular carcinoma. N: groups of 20 mice described in the full text. Country: Saudi Arabia (King Faisal University). Dose: MBZ 100 mg/kg/day orally, from day 45 to day 120. Funder: not stated in the record. Declared conflicts: 'The authors declare no competing interests.' Comparator: vehicle, sorafenib alone, and the combination. Study type: animal.